Arturo Loaiza-Bonilla: Yelena Janjigian’s Phase III Claudin 18.2 ADC Data Mark a Milestone at ESMO 2026
Arturo Loaiza-Bonilla and Yelena Janjigian/LinkedIn

Arturo Loaiza-Bonilla: Yelena Janjigian’s Phase III Claudin 18.2 ADC Data Mark a Milestone at ESMO 2026

Arturo LoAIza-Bonilla, Medical Oncologist and Principal Investigator at St. Luke’s University Health Network, shared on LinkedIn:

“Kudos to Dr. Yelena Janjigian for the great progress her ongoing research has brought to the GI Oncology field, she is an esteemed colleague and outstanding collaborator. And congratulations for a fantastic ESMO26 meeting as Scientific Committee Co-Chair, and the groundbreaking phase 3 data on Claudin 18.2 ADC.

Memorial Sloan Kettering Cancer Center certainly has the best representation at ESMO.”

You can also read: 10 Gastroesophageal Cancer Trials to Watch at ESMO 2026 

Arturo Loaiza-Bonilla: Yelena Janjigian’s Phase III Claudin 18.2 ADC Data Mark a Milestone at ESMO 2026